BGLC - CIK 0001737523
The table below shows BioNexus Gene Lab Corp's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1.84M | -$2.09M | -$1.82M | $551.82K | $9.16K | $552.68K |
| Capital expenditure | $36.97K | $226.99K | $149.40K | $0.00 | $3.16K | $421.62K |
| Investing cash flow | $944.75K | $418.20K | -$1.79M | -$450.50K | -$490.57K | $1.32M |
| Dividends paid | - | - | - | - | - | - |
BioNexus Gene Lab Corp reported operating cash flow of -$1.84M for fiscal year 2025. That is up 12.2% from -$2.09M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$274.08K (FY 2018) to -$1.84M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $298.84K | $3.98K | $6.27M | $108.17K | -$28.22K | -$4.95K |